Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA
Research To Practice | Oncology Videos · Dr. Neil Love
October 23, 202554m 59s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Eunice S Wang, including the following topics:
- Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00)
- All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39)
- Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07)
- Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14)
- Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24)
- Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54)
- Key clinical data with approved and investigational menin inhibitors for AML; current and potential integration of menin inhibitors in the AML treatment algorithm (42:30)